Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Am J Med Sci. 2010 Feb;339(2):169-73. doi: 10.1097/MAJ.0b013e3181c4af27.
Hepatocellular carcinoma (HCC) occurring in "noncirrhotic" hepatitis C virus (HCV)-infected patients has been reported; but the exact prevalence or incidence has not been described before.
We conducted a systematic review of literature: Ovid was used to search the literature from January 1, 1990, to September 1, 2008. Articles containing "HCC" keywords (hepatocellular carcinoma, hepatoma, liver cancer) were combined with the word "cirrhosis" or "fibrosis" and with "absence" keywords [noncirrhotic, absence, without]. Two hundred articles were selected and screened according to predesigned exclusion and inclusion criteria.
Nineteen articles met the inclusion criteria. The estimated prevalence of noncirrhotic HCC ranged from 6.7% to 50.1%. The pooled prevalence estimates for HCV in noncirrhotic HCC ranged from 0% and 68.4% according to the geographic location. Reports from Japan had the highest estimated pooled prevalence of HCV (55.01%) followed by Italy (29.95%).
HCV can occur in patients with HCC without cirrhosis, but the true incidence and prevalence are very difficult to ascertain. Further studies are needed to define this group of patients.
在丙型肝炎病毒（HCV）感染的“非肝硬化”患者中发生肝细胞癌（HCC）已有报道；但确切的流行率或发病率尚未被描述。
我们进行了文献系统回顾：Ovid 被用来搜索从 1990 年 1 月 1 日至 2008 年 9 月 1 日的文献。包含“HCC”关键词（肝细胞癌、肝癌、肝肿瘤）的文章与“肝硬化”或“纤维化”一词结合，并与“无”关键词[非肝硬化、无、没有]结合。根据预设的排除和纳入标准，选择了 200 篇文章进行筛选。
19 篇文章符合纳入标准。非肝硬化 HCC 的估计患病率范围为 6.7%至 50.1%。根据地理位置，非肝硬化 HCC 中 HCV 的合并患病率估计值范围从 0%到 68.4%。来自日本的报告中 HCV 的估计合并患病率最高（55.01%），其次是意大利（29.95%）。
HCV 可发生于无肝硬化的 HCC 患者，但确切的发病率和患病率很难确定。需要进一步的研究来确定这组患者。
